Plus Therapeutics PSTV Stock
Plus Therapeutics Price Chart
Plus Therapeutics PSTV Financial and Trading Overview
| Plus Therapeutics stock price | 4.08 USD |
| Previous Close | 4.2 USD |
| Open | 4.13 USD |
| Bid | 2.96 USD x 200 |
| Ask | 5.1 USD x 200 |
| Day's Range | 3.95 - 4.18 USD |
| 52 Week Range | 2.9 - 23.5 USD |
| Volume | 392.06K USD |
| Avg. Volume | 316.04K USD |
| Market Cap | 27.4M USD |
| Beta (5Y Monthly) | 1.366 |
| PE Ratio (TTM) | 0.18460111 |
| EPS (TTM) | 21.56 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36 USD |
PSTV Valuation Measures
| Enterprise Value | 13.01M USD |
| Trailing P/E | 0.18460111 |
| Forward P/E | -1.6617954 |
| PEG Ratio (5 yr expected) | 2.45 |
| Price/Sales (ttm) | 5.2871304 |
| Price/Book (mrq) | 2.2834194 |
| Enterprise Value/Revenue | 2.51 |
| Enterprise Value/EBITDA | -0.704 |
Trading Information
Plus Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.366 |
| 52-Week Change | -16.21% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 23.5 USD |
| 52 Week Low | 2.9 USD |
| 50-Day Moving Average | 5.84 USD |
| 200-Day Moving Average | 9.87 USD |
PSTV Share Statistics
| Avg. Volume (3 month) | 316.04K USD |
| Avg. Daily Volume (10-Days) | 187.5K USD |
| Shares Outstanding | 6.88M |
| Float | 6.48M |
| Short Ratio | 7.75 |
| % Held by Insiders | 1.48% |
| % Held by Institutions | 10.38% |
| Shares Short | 1.14M |
| Short % of Float | 16.69% |
| Short % of Shares Outstanding | 16.62% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -230.23% |
| Operating Margin (ttm) | -692.51% |
| Gross Margin | -83.094% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -73.81% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 5.18M USD |
| Revenue Per Share (ttm) | 1.12 USD |
| Quarterly Revenue Growth (yoy) | -2.90% |
| Gross Profit (ttm) | -4306000 USD |
| EBITDA | -18486000 USD |
| Net Income Avi to Common (ttm) | -11931000 USD |
| Diluted EPS (ttm) | 21.56 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 15.11M USD |
| Total Cash Per Share (mrq) | 2.2 USD |
| Total Debt (mrq) | 725K USD |
| Total Debt/Equity (mrq) | 6.06 USD |
| Current Ratio (mrq) | 2.266 |
| Book Value Per Share (mrq) | 1.743 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20841000 USD |
| Levered Free Cash Flow (ttm) | -15108250 USD |
Profile of Plus Therapeutics
| Country | United States |
| State | TX |
| City | Houston |
| Address | 6420 LEVIT GREEN BOULEVARD |
| ZIP | 77021 |
| Phone | 737 255 7194 |
| Website | https://plustherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 28 |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Q&A For Plus Therapeutics Stock
What is a current PSTV stock price?
Plus Therapeutics PSTV stock price today per share is 4.08 USD.
How to purchase Plus Therapeutics stock?
You can buy PSTV shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Plus Therapeutics?
The stock symbol or ticker of Plus Therapeutics is PSTV.
Which industry does the Plus Therapeutics company belong to?
The Plus Therapeutics industry is Biotechnology.
How many shares does Plus Therapeutics have in circulation?
The max supply of Plus Therapeutics shares is 6.88M.
What is Plus Therapeutics Price to Earnings Ratio (PE Ratio)?
Plus Therapeutics PE Ratio is 0.18923934 now.
What was Plus Therapeutics earnings per share over the trailing 12 months (TTM)?
Plus Therapeutics EPS is 21.56 USD over the trailing 12 months.
Which sector does the Plus Therapeutics company belong to?
The Plus Therapeutics sector is Healthcare.
Plus Therapeutics PSTV included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
146.53 USD — |
-0.75
|
— — | 144.14 USD — | 148.72 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}